clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2025-3-3-67-74clinicaloncology-137Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSКлинический случай применения интратекального введения этопозида у пациента с лептоменингеальным метастазированием немелкоклеточного рака легкогоА clinical case of etoposide intrathecal administration in a patient with leptomeningial metastasis of nonsmall cell lung cancerhttps://orcid.org/0000-0001-9413-367XФатееваА. В.FateevaAnastasia A.

Фатеева Анастасия Валерьевна

690002, Приморский край, г. Владивосток, пр-т Острякова, д. 2 

141407, Московская область, городской округ Химки, Куркинское шоссе, д. 11 

2, Ostryakova Ave., Primorsky Krai, Vladivostok, 690002

11, Kurkinskoe highway, Moscow region, Khimki, 141407

ralise@bk.ruФГБОУ ВО «Тихоокеанский государственный медицинский университет»; ГБУЗ Московской области «Химкинская клиническая больница»РоссияPacific State Medical University; Khimki Clinical HospitalRussian Federation202528012026336774Copyright © Фатеева А.В., 20262026Фатеева А.В.Fateeva A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/137

Лептоменингеальное метастазирование немелкоклеточного рака легкого представляет собой редкую и сложную клиническую ситуацию. Отсутствие рандомизированных клинических исследований осложняет процесс выбора подходящих методов лечения с доказанной эффективностью для данной когорты пациентов и зачастую ставит клиницистов в затруднительное положение. В связи с этим поиск возможных потенциально эффективных вариантов лечения для пациентов с лептоменингеальными метастазами, является важным направлением. Здесь представлено описание клинического случая лечения пациента с плоскоклеточным раком легкого с применением интратекальной химиотерапии этопозидом.

Leptomeningial metastasis of non-small cell lung cancer is a rare and complex clinical case. The lack of randomized clinical trials complicates the process of choosing appropriate treatment methods with the proven efficacy for this cohort of patients and often puts clinicians in a difficult position. Therefore, the search for possible potentially effective treatment options for patients with leptomeningeal metastases is an important direction. Here is a description of a clinical case of a patient with squamous cell lung cancer treatment using intrathecal chemotherapy with etoposide.

плоскоклеточный рак легкоголептоменингеальное метастазированиеэтопозидинтратекальная химиотерапияпоражение ЦНСsquamous cell lung cancerleptomeningial metastasisetoposideintrathecal chemotherapyCNS lesionReferencesCagney D.N., Martin A.M., Catalano P.J., Redig A.J., Lin N.U., Lee E.Q. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study // NeuroOncol. 2017. Vol. 19. Р. 1511–1521. https://doi.org/10.1093/neuonc/nox077.Cagney D.N., Martin A.M., Catalano P.J., Redig A.J., Lin N.U., Lee E.Q. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study // NeuroOncol. 2017. Vol. 19. Р. 1511–1521. https://doi.org/10.1093/neuonc/nox077.Kang Y., Jin Y., Li Q., Yuan X. Advances in lung cancer driver genes associated with brain metastasis // Front Oncol. 2020. Vol. 10606300. https://doi.org/10.3389/fonc.2020.606300.Kang Y., Jin Y., Li Q., Yuan X. Advances in lung cancer driver genes associated with brain metastasis // Front Oncol. 2020. Vol. 10606300. https://doi.org/10.3389/fonc.2020.606300.Wang B., Guo H., Xu H., Yu H., Chen Y., Zhao G. Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer // Cells. 2021. Vol. 10. Р. 2620 https://doi.org/10.3390/cells10102620.Wang B., Guo H., Xu H., Yu H., Chen Y., Zhao G. Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer // Cells. 2021. Vol. 10. Р. 2620 https://doi.org/10.3390/cells10102620.Pellerino A., Internò V., Muscolino E., Mo F., Bruno F., Pronello E. et al. Leptomeningeal metastases from non-small cell lung cancer: State of the art and recent advances // J.Cancer Metastasis Treat. 2020. Vol. 6, No. 41. https://doi.org/10.20517/2394-4722.2020.80.Pellerino A., Internò V., Muscolino E., Mo F., Bruno F., Pronello E. et al. Leptomeningeal metastases from non-small cell lung cancer: State of the art and recent advances // J.Cancer Metastasis Treat. 2020. Vol. 6, No. 41. https://doi.org/10.20517/2394-4722.2020.80.Le Rhun E., Weller M., van den Bent M., Brandsma D., Furtner J., Ruda R. et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // ESMO Open. 2023. Vol. 8101624. https://doi.org/10.1016/j.esmoop.2023.101624.Le Rhun E., Weller M., van den Bent M., Brandsma D., Furtner J., Ruda R. et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // ESMO Open. 2023. Vol. 8101624. https://doi.org/10.1016/j.esmoop.2023.101624.Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases // ESMO Open. 2019. Vol. 4. e000507.Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases // ESMO Open. 2019. Vol. 4. e000507.Gwak H.S. Joo J. Kim S. Yoo H. Shin S.H. Han J.Y. et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer // J. Thorac. Oncol. 2013. Vol. 8. Р. 599–605. https://doi.org/10.1097/JTO.0b013e318287c943.Gwak H.S. Joo J. Kim S. Yoo H. Shin S.H. Han J.Y. et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer // J. Thorac. Oncol. 2013. Vol. 8. Р. 599–605. https://doi.org/10.1097/JTO.0b013e318287c943.Riess J.W., Nagpal S., Iv M., Zeineh M., Gubens M.A. Ramchandran K. et al. Prolonged survival of patients with nonsmall-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era // Clin. Lung Cancer. 2014. Vol. 15. Р. 202–206. https://doi.org/10.1016/j.cllc.2013.12.009.Riess J.W., Nagpal S., Iv M., Zeineh M., Gubens M.A. Ramchandran K. et al. Prolonged survival of patients with nonsmall-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era // Clin. Lung Cancer. 2014. Vol. 15. Р. 202–206. https://doi.org/10.1016/j.cllc.2013.12.009.Yang J.C., Kim S.W., Kim D.W., Lee J.S., Cho B.C., Ahn J.S. et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM Study // J.Clin.Oncol. 2020. Vol. 38. Р. 538–547. https://doi.org/10.1200/JCO.19.00457.Yang J.C., Kim S.W., Kim D.W., Lee J.S., Cho B.C., Ahn J.S. et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM Study // J.Clin.Oncol. 2020. Vol. 38. Р. 538–547. https://doi.org/10.1200/JCO.19.00457.Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M. et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors // J. Thorac. Oncol. 2013. Vol. 8. Р. 185–191. https://doi.org/10.1097/JTO.0b013e3182773f21.Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M. et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors // J. Thorac. Oncol. 2013. Vol. 8. Р. 185–191. https://doi.org/10.1097/JTO.0b013e3182773f21.Le Rhun E., Devos P., Weller J., Seystahl K., Mo F., Compter A. et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors // NeuroOncol. 2021. Vol. 23. Р. 1100–1112. https://doi.org/10.1093/neuonc/noaa29.Le Rhun E., Devos P., Weller J., Seystahl K., Mo F., Compter A. et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors // NeuroOncol. 2021. Vol. 23. Р. 1100–1112. https://doi.org/10.1093/neuonc/noaa29.Alexander M., Lin E., Cheng H. Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations // Curr. Treat. Options Oncol. 2020. Vol. 21. Р. 72. https://doi.org/10.1007/s11864-020-00759-3.Alexander M., Lin E., Cheng H. Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations // Curr. Treat. Options Oncol. 2020. Vol. 21. Р. 72. https://doi.org/10.1007/s11864-020-00759-3.Boogerd W., van den Bent M.J., Koehler P.J. et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study // Eur. J. Cancer. 2004. Vol. 40. Р. 2726–2733.Boogerd W., van den Bent M.J., Koehler P.J. et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study // Eur. J. Cancer. 2004. Vol. 40. Р. 2726–2733.Le Rhun E., Wallet J., Mailliez A. et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer // NeuroOncol. 2020. Vol. 22. Р. 524–538.Le Rhun E., Wallet J., Mailliez A. et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer // NeuroOncol. 2020. Vol. 22. Р. 524–538.Grossman S.A. Finkelstein D.M. Ruckdeschel J.C. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group // J. Clin. Oncol. 1993. Vol. 11. Р. 561–569.Grossman S.A. Finkelstein D.M. Ruckdeschel J.C. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group // J. Clin. Oncol. 1993. Vol. 11. Р. 561–569.Fan C., Zhao Q., Li L. et al. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615) // J. Thorac. Oncol. 2021. Vol. 16. Р. 1359–1368.Fan C., Zhao Q., Li L. et al. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615) // J. Thorac. Oncol. 2021. Vol. 16. Р. 1359–1368.Glitza Oliva I.C., Ferguson S.D., Bassett R. et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results // Nat. Med. 2023. Vol. 29. Р. 898–905.Glitza Oliva I.C., Ferguson S.D., Bassett R. et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results // Nat. Med. 2023. Vol. 29. Р. 898–905.Fleischhack G., Reif S., Hasan C. et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours // Br.J.Cancer. 2001. Vol. 84, No. 11. Р. 1453–1459.Fleischhack G., Reif S., Hasan C. et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours // Br.J.Cancer. 2001. Vol. 84, No. 11. Р. 1453–1459.Min Jae Park Prolonged Response of Meningeal Carcinomatosis from Non-small Cell Lung Cancer to Salvage Intrathecal Etoposide Subsequent to Failure of First-Line Methotrexate: A Case Report and Literature Review // Am.J.Case Rep. 2015. Vol. 16. Р. 224–227. Published online 2015 Apr 16. doi: 10.12659/AJCR.894061.Min Jae Park Prolonged Response of Meningeal Carcinomatosis from Non-small Cell Lung Cancer to Salvage Intrathecal Etoposide Subsequent to Failure of First-Line Methotrexate: A Case Report and Literature Review // Am.J.Case Rep. 2015. Vol. 16. Р. 224–227. Published online 2015 Apr 16. doi: 10.12659/AJCR.894061.Bonomi Ph. et al. Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial // J. Clin. Oncol. 2000. Vol. 18, Nо. 3. https://doi.org/10.1200/JCO.2000.18.3.623.Bonomi Ph. et al. Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial // J. Clin. Oncol. 2000. Vol. 18, Nо. 3. https://doi.org/10.1200/JCO.2000.18.3.623.

The authors declare that there are no conflicts of interest present.